Eurofins Global Central Laboratory announced that is has achieved an important strategic milestone with the opening of a new Central Laboratory in Bangalore, India. This new laboratory complements the Eurofins Global Central Laboratory current global footprint of wholly-owned laboratory facilities in the United States, Europe, Singapore, and China.
René van Erp, Managing Director Eurofins Global Central Laboratory, explains: “Eurofins Global Central Laboratory is uniquely positioned since only few Contract Research Organizations (CROs) offer a similar global footprint. This expansion of our global footprint allows us to bring more value to our customers, and makes Eurofins Global Central Laboratory a unique world-wide source for laboratory testing in clinical trials.”
Located in Bangalore, known as the Knowledge Hub in India, the facility will operate congruently to the other Eurofins Central Laboratory locations. Successfully operational since the 1st of September, the Bangalore central laboratory facility offers a full package of safety testing, as well as biomarker testing. Upon its launch, the facility is certified with the National Glycohemoglobin Standardization Program (NGSP) Level 1 accreditation, and should achieve NABL and CAP accreditations within its first year of operation. The Bangalore facility’s location gives it easy access to the transportation infrastructure in India, enabling close control over transportation and maintenance of specimen integrity.